Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Troy Ignelzi Acquires 5,500 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) CFO Troy Ignelzi bought 5,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 21st. The shares were acquired at an average cost of $26.10 per share, for a total transaction of $143,550.00. Following the completion of the purchase, the chief financial officer owned 15,500 shares in the company, valued at $404,550. This trade represents a 55.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Rapport Therapeutics Trading Up 5.9%

Rapport Therapeutics stock opened at $26.53 on Friday. Rapport Therapeutics, Inc. has a 52-week low of $23.75 and a 52-week high of $52.93. The company’s 50 day moving average is $39.44 and its two-hundred day moving average is $39.02.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, equities analysts forecast that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Institutional Trading of Rapport Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV purchased a new stake in Rapport Therapeutics during the 1st quarter worth about $30,000. Sterling Capital Management LLC boosted its position in shares of Rapport Therapeutics by 597.9% during the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after acquiring an additional 843 shares in the last quarter. State of Wyoming purchased a new position in shares of Rapport Therapeutics in the 2nd quarter valued at about $65,000. Meeder Asset Management Inc. purchased a new position in shares of Rapport Therapeutics in the 2nd quarter valued at about $116,000. Finally, AlphaCentric Advisors LLC increased its holdings in shares of Rapport Therapeutics by 6.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock valued at $201,000 after acquiring an additional 408 shares during the last quarter.

Analyst Upgrades and Downgrades

RAPP has been the subject of several analyst reports. TD Cowen reissued a “buy” rating on shares of Rapport Therapeutics in a research note on Tuesday. Wolfe Research started coverage on Rapport Therapeutics in a research report on Thursday, October 15th. They issued an “outperform” rating and a $50.00 price target on the stock. William Blair started coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating for the company. JonesTrading lifted their price objective on Rapport Therapeutics from $50.00 to $82.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, BTIG Research boosted their price objective on Rapport Therapeutics from $75.00 to $89.00 and gave the stock a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $68.36.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The candidate produced statistically significant placebo-adjusted improvements in YMRS and CGI-BP mania-severity scores. Rapport plans to begin Phase 3 trials, potentially expanding RAP-219’s commercial opportunity beyond epilepsy. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts increased or maintained bullish valuations. JonesTrading raised its target to $82, while BTIG reportedly lifted its target to $89. Raymond James raised its target to $86, and HC Wainwright reaffirmed its Buy rating. The consensus target is approximately $68.36, well above recent trading levels. BTIG price target increase
• Positive Sentiment: Company insiders made substantial open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while four directors purchased an additional 52,594 shares. The combined purchases were worth approximately $1.57 million and may signal management confidence following the clinical update. SEC insider filings
• Neutral Sentiment: RAP-219’s move toward Phase 3 is an important milestone, but investors still face clinical, regulatory, financing, and commercialization uncertainty typical of a clinical-stage biotechnology company.
• Negative Sentiment: The clinical results may have been less decisive than some investors expected. Reports indicated that portions of the data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport also remains unprofitable; its latest quarterly loss exceeded analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. Rapport bipolar data report

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.